Sign in
CompletedPhase 1/2

NVG-291 in Spinal Cord Injury Subjects

Key facts

Who runs it
NervGen Pharma
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
24 people enrolled
Started
8 Aug 2023
Ended
21 Jan 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NVG-291
  • Placebo Injection
Record updated
9 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (62)Hide the full registry criteria

Who can take part

  • A subject must provide written informed consent in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent
  • Cervical spinal cord injury (SCI) resulting from acute physical trauma
  • Males and females
  • Age 18 to 75 years, inclusive
  • Cervical SCI, incomplete, with a neurological level of injury at C7 or higher
  • Had incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic Cohort 1) OR within 20 days to 90 days inclusive (Subacute Cohort 2) at time of randomization
  • Chronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support)
  • Must have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows:
  • Chronic Cohort 1: Less than or equal to Level 14
  • Subacute Cohort 2: Less than or equal to Level 10
  • Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
  • Chronic Cohort 1:
  • Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity
  • Must have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above
  • Subacute Cohort 2:
  • Must have some voluntary (nonzero) force measured by grip dynamometry in at least one upper extremity
  • Must have no more than one Prehension Ability grasp pattern score = 3 in at least one upper extremity
  • Must not have a Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above
  • Presence of Motor Evoked Potentials (MEPs):
  • Chronic Cohort 1: In two specific target muscle groups
  • Subacute Cohort 2: In one specific target muscle group
  • Must be fluent in English
  • Must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures

Who cannot take part

  • Metal implant in the head that is likely to interfere with MRI analysis
  • History of substance abuse within 12 months prior to screening, based on medical records or self-report
  • Prior treatment with cell therapy delivered into the central nervous system (intrathecal or intraparenchymal)
  • Severe neuropathic pain inadequately controlled by medication
  • Received botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months
  • Received 4-aminopyridine within 7 days of first dose
  • Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide
  • Received a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization
  • Receiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent or within 4 weeks of randomization, whichever is longer
  • Currently receiving neuromuscular stimulation
  • Currently receiving vagal or phrenic nerve stimulation
  • Malignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ
  • Any disease, concomitant injury (such as significant traumatic brain injury), or condition that could interfere with the performance or interpretation of the protocol-specified assessments, in the opinion of the investigator
  • Nontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, malignancy, radiation injury, surgical complications, or other disease process)
  • Any condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation
  • History of uncontrolled seizures, or:
  • Chronic Cohort 1: Any seizure within the last 6 months
  • Subacute Cohort 2: Any seizure occurring 1 week or more after the SCI
  • Any neurological condition that is considered to interfere with performance or likely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia
  • History of a cardiac pacemaker or pacemaker wires
  • Prosthetic heart valves
  • Any other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation
  • History of medically significant hepatic disease or evidence of impaired liver function based on initial laboratory testing
  • Severe renal insufficiency, defined as eGFR < 30 mL/min/1.73m2
  • SCI due to gunshot wound or penetrating injury
  • Two or more (noncontiguous) spinal cord lesions
  • MRI or CT evidence of anatomically complete spinal cord transection
  • Any form of ventilatory dependence
  • Pregnant or breastfeeding
  • Evidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma
  • Body mass index (BMI) > 40 kg/m2
  • Intrathecal opioid use
  • Currently participating in an interventional clinical trial
  • Any implanted internal spinal cord stimulator
  • Chronic Cohort 1 only: Any contraindication to baseline and on-study MRIs, such as:
  • Ferromagnetic metallic particles in the body
  • Baclofen pump
  • Vascular clips in the head
  • Severe claustrophobia impeding ability to participate in an imaging study

Where in United States

  • Shirley Ryan AbilityLabChicago, United States

About the trial

What the trial wants to find out

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

The 2 groups in the trial

  • NVG-291 for SC InjectionTreatment being tested

    NVG-291 administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.

    Treatment: NVG-291

  • Placebo for SC InjectionPlacebo, for comparison

    Matching placebo administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.

    Treatment: Placebo Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)
Publications
Record updated
9 November 2026